Abstract:The reaction of copper(I) halides with 2-thiouracil (TUC), 6-methyl-2-thiouacil (MTUC), and 4-methyl-2-mercaptopyrimidine (MPMTH) in the presence of triphenylphosphine (tpp) in a 1:1:2 molar ratio results in a mixed-ligand copper(I) complex with the formulas [Cu2(tpp)4(TUC)Cl] (1), [Cu2(tpp)4(MTUC)Cl] (2), [Cu(tpp)2(MPMTH)Cl]·(1)/2CH3OH (3), [Cu(tpp)2(MTUC)Br] (4), and [Cu(tpp)2(MTUC)I]·(1)/2CH3CN (5). The complexes have been characterized by FT-IR, (1)H NMR, and UV-vis spectroscopic techniques and single-crys… Show more
“…For the title compound, τ 4 = 0.93 is slightly higher than the τ 4 = 0.90 of the [CuBr(PPh 3 ) 3 ] complex, which means that the overall tetrahedral character around the Cu-atom was not substantially altered by the substitution of the PPh 3 group by the -thione ligand. In general, all the interatomic distances are comparable to the corresponding distances reported in identical Cu-complexes [14,28,[48][49][50]52]. In the title compound, the Cu-Br distance (2.5412(2) Å) is slightly longer, while the Cu-P average distance of 2.275 Å became shorter compared to the respective distances (2.497(1) Å and 2.333 Å) observed in the parent compound, which is related to the thione-S donor substitution in the title compound.…”
Section: Crystal Structure Studysupporting
confidence: 79%
“…shows the molecular structure of [CuBr(PPh3)2(C6H8N2S)]. The geomet rical feature of the molecule resembles the parent [CuBr(PPh3)3] complex and other simila Cu(I) halide complexes with CuXSP2 cores[14,28,[48][49][50]. The heavily distorted tetrahedra coordination of the copper compound is realized by the S-atom of the -thione, the P-atom of phosphine, and bromo ligands.…”
CuBr(PPh3)2(4,6-dimethylpyrimidine-2-thione) (Cu-L) was synthesized by stirring CuBr(PPh3)3 and 4,6-dimethylpyrimidine-2-thione in dichloromethane. The crystal structure of Cu-L was obtained, and indicated that the complex adopts a distorted tetrahedral structure with several intramolecular hydrogen bonds. Moreover, a centrosymmetric dimer is formed by the intermolecular hydrogen bonding of the bromine acceptor created by symmetry operation 1−x, 1−y, 1−z to the methyl group (D3 = C42) of the pyrimidine–thione ligand. HSA-binding of Cu-L and its ligand were evaluated, revealing that Cu-L binds to HSA differently than its ligand. The HSA-bindings were modeled by molecular docking, which suggested that Cu-L binds to the II A domain while L binds between the I B and II A domains. Anticancer activities toward OVCAR-3 and HeLa cell lines were tested and indicated the significance of the copper center in enhancing the cytotoxic effect; negligible toxicities for L and Cu-L were observed towards a non-cancer cell line. The current study highlights the potential of copper(I)-phosphine complexes containing thione ligands as therapeutic agents.
“…For the title compound, τ 4 = 0.93 is slightly higher than the τ 4 = 0.90 of the [CuBr(PPh 3 ) 3 ] complex, which means that the overall tetrahedral character around the Cu-atom was not substantially altered by the substitution of the PPh 3 group by the -thione ligand. In general, all the interatomic distances are comparable to the corresponding distances reported in identical Cu-complexes [14,28,[48][49][50]52]. In the title compound, the Cu-Br distance (2.5412(2) Å) is slightly longer, while the Cu-P average distance of 2.275 Å became shorter compared to the respective distances (2.497(1) Å and 2.333 Å) observed in the parent compound, which is related to the thione-S donor substitution in the title compound.…”
Section: Crystal Structure Studysupporting
confidence: 79%
“…shows the molecular structure of [CuBr(PPh3)2(C6H8N2S)]. The geomet rical feature of the molecule resembles the parent [CuBr(PPh3)3] complex and other simila Cu(I) halide complexes with CuXSP2 cores[14,28,[48][49][50]. The heavily distorted tetrahedra coordination of the copper compound is realized by the S-atom of the -thione, the P-atom of phosphine, and bromo ligands.…”
CuBr(PPh3)2(4,6-dimethylpyrimidine-2-thione) (Cu-L) was synthesized by stirring CuBr(PPh3)3 and 4,6-dimethylpyrimidine-2-thione in dichloromethane. The crystal structure of Cu-L was obtained, and indicated that the complex adopts a distorted tetrahedral structure with several intramolecular hydrogen bonds. Moreover, a centrosymmetric dimer is formed by the intermolecular hydrogen bonding of the bromine acceptor created by symmetry operation 1−x, 1−y, 1−z to the methyl group (D3 = C42) of the pyrimidine–thione ligand. HSA-binding of Cu-L and its ligand were evaluated, revealing that Cu-L binds to HSA differently than its ligand. The HSA-bindings were modeled by molecular docking, which suggested that Cu-L binds to the II A domain while L binds between the I B and II A domains. Anticancer activities toward OVCAR-3 and HeLa cell lines were tested and indicated the significance of the copper center in enhancing the cytotoxic effect; negligible toxicities for L and Cu-L were observed towards a non-cancer cell line. The current study highlights the potential of copper(I)-phosphine complexes containing thione ligands as therapeutic agents.
“…The resonance signals at 7.899–7.873 ppm (d) (H[C 3 ]), 7.328–7.286 ppm (t) (H[C 6 ]), 7.140–7.096 ppm (m) (H[C 4 ]), 7.050–7.008 ppm (m) (H[C 5 ], H[C 5′ ], H[C 4′ ]), and 6.711–6.674 (t) ppm (H[C 6′ ]) (Chart ) are attributed to the aromatic H located in mefH (Figures S9–S12). Moreover, the 1 H NMR spectra of the pnictogen derivatives tpE are dominated by the presence of two multiplet signals that are attributed to the phenyl at 7.376–7.354 ppm (t) (H[C a ]) and 7.239–7.171 ppm (m) (H[C c ] and H[C d ]) (tpP), , 7.366–7.341 ppm (t) (H[C a ]) and 7.260–7.221 ppm (m) (H[C c ] and H[C d ]) (tpAs), , and 7.394–7.312 ppm (m) (H[C a ], H[C c ], and H[C d ]) (tpSb) (Chart ). These signals are observed at 7.957–7.933 ppm (H[C 3 ]), 7.153–7.110 ppm (H[C 6 ]), 7.053–7.014 ppm (H[C 4 ], 6.863–6.836 ppm (H[C 5 ], H[C 5′ ], H[C 4′ ]), and 6.635–6.596 ppm (H[C 6′ ]) in the spectrum of 1 (Figure S9).…”
{[Ag8(Mef)8(μ2-S,O-DMSO)2(μ2-O-DMSO)2(O-DMSO)8]·2(H2O)} (1), [Ag(Mef)(tpP)2] (2),
[Ag(Mef)(tpAs)3] (3), and {2 [Ag(Mef)(tpSb)3] (DMSO)} (4) were obtained by the conjugation
of mefenamic acid (MefH), a nonsteroidal anti-inflammatory drug (NSAID),
with a mitochondriotropic derivative of pnictogen tpE (tp = triphenyl
group; E = P, As, and Sb) through silver(I). Their hydrophilicity
was adjusted by their dispersion into sodium lauryl sulfate (SLS),
forming SLS@1–4. 1–4 and SLS@1–4 were characterized
by their spectral data and X-ray crystallography. They inhibit the
proliferation of human breast adenocarcinoma cells MCF-7 (hormone-dependent
(HD)) and MDA-MB-231 (hormone-independent (HI)). X-ray fluorescence
reveals the Ag cellular uptake. The in vitro and in vivo nongenotoxicity was confirmed with micronucleus
(MN), Artemia salina, and Allium cepa assays. Their mechanism of action was studied by cell morphology,
DNA fragmentation, acridine orange/ethidium bromide (AO/EB) staining,
cell cycle arrest, mitochondrial membrane permeabilization tests,
DNA binding affinity, and LOX inhibitory activity and was rationalized
by regression analysis.
“…The antineoplastic potential of the metal-based complexes dependent on the nature of the ligands, and metallodrugs complexes containing nucleobases and their derivatives have been previously explored. These include ruthenium(II) complexes with thymine and 5-fluorouracil 9,11 ; palladium(II) complexes with 2-thiouracil ligands 17 ; gold(I) complexes with 2-thiouracil, 2-thiocytosine and 2-mercaptopyridine 18 ; and copper(I) complexes with 2-thiouracil, 6-methyl-2-thiouacil and 4-methyl-2-mercaptopyrimidine 19 . Recently, we synthesized four ruthenium(II) complexes with thiouracil derivatives using [RuCl 2 (PPh 3 ) 3 ] and [RuCl 2 (PPh 3 ) 2 (dppb)] complexes as precursors.…”
Ruthenium(II) complexes with 6-methyl-2-thiouracil
cis
-[Ru(6m2tu)
2
(PPh
3
)
2
] (
1
) and [Ru(6m2tu)
2
(dppb)] (
2
) (where PPh
3 =
triphenylphosphine; dppb = 1,4-bis(diphenylphosphino)butane; and 6m2tu = 6-methyl-2-thiouracil) are potent cytotoxic agents and able to bind DNA. The aim of this study was to evaluate
in vitro
cellular underlying mechanism and
in vivo
effectiveness of these ruthenium(II) complexes in human acute promyelocytic leukemia HL-60 cells. Both complexes displayed potent and selective cytotoxicity in myeloid leukemia cell lines, and were detected into HL-60 cells. Reduction of the cell proliferation and augmented phosphatidylserine externalization, caspase-3, -8 and -9 activation and loss of mitochondrial transmembrane potential were observed in HL-60 cells treated with both complexes. Cotreatment with Z-VAD(OMe)-FMK, a pan-caspase inhibitor, reduced Ru(II) complexes-induced apoptosis. In addition, both metal complexes induced phosphorylation of histone H2AX (S139), JNK2 (T183/Y185) and p38α (T180/Y182), and cotreatment with JNK/SAPK and p38 MAPK inhibitors reduced complexes-induced apoptosis, indicating DNA double-strand break and activation of caspase-mediated apoptosis through JNK/p38 pathways. Complex
1
also reduced HL-60 cell growth in xenograft model. Overall, the outcome indicated the ruthenium(II) complexes with 6-methyl-2-thiouracil as a novel promising antileukemic drug candidates.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.